The US FDA has approved safinamide as adjunctive therapy in Parkinson's disease to increase "on" time
A 10-month-old girl admitted to PICU with sudden onset of movement disorder was found to have ingested a foreign body.
While their are other factors more strongly associated with risk of cerebral palsy, maternal obesity is modifiable and therefore should be studied further.
Improvements in excessive daytime sleepiness and daytime alertness were observed in the bright light therapy group.
Neurofilament light chain, a blood biomarker, demonstrated high accuracy for distinguishing atypical parkinsonian disorders from Parkinson's disease.
Comorbid psychological conditions affect cognitive function in Parkinson's disease, and treatment can be complicated by overlapping symptoms.
New findings suggest that dysregulation of mitochondrial DNA homeostasis may be a key factor in the pathogenesis of neuronal loss in people with Parkinson's disease.
During cognitive co-activation, the levodopa effect was significantly smaller.
The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.
A combination of age and clinical scores better predicted cognitive impairment than age alone.
Adjunctive treatment with safinamide helps increase "on" time in patients with Parkinson's disease.
Mutated GCH1 gene was associated with a 23% increased risk of Parkinson's disease, especially in men 50 years or younger.
A powdered version of the common treatment may help to relieve "off" periods.
The small study documented several cases of denervation and increased thermal thresholds in patients treated with LCIG.
Pharmacologic intervention is the current standard of care for Parkinson's disease, yet medications frequently fail to control some symptoms, including tremor and postural instability.
The researchers found that GBA carriers were at greater risk for dementia and death (hazard ratios, 3.16 and 1.85, respectively) than non-carriers.
Vascular disease can have a negative impact on cognition and motor phenotype in PD.
Cognitive training and tDCS, alone or combined, appear to benefit cognition and QOL in Parkinson's patients
The standard MoCA evaluation was unable to predict decline in fluctuating attention and visual memory.
Over fifty percent of respondents reported using 1 or more alternative therapies.
The 4th World Parkinson Congress takes September 20-23, 2016 in Portland, Oregon.
The pathogenesis of GBA on PD is unclear, although several studies have pointed to disruptions of different molecular pathways that contribute to disease onset.
Smoking during pregnancy has been linked withlong-term neurodevelopmental abnormalities and child behavioral problems.
Patients in the treatment group experienced significant improvements at 3 months and through 12 months.
The potential role of active music therapy in ameliorating motor and nonmotor symptoms of Parkinson's disease (PD) was examined by researchers.
All but one type of statin was associated with a dose-dependent neurprotective benefit against Parkinson's.
Myoclonic seizures may be easily mistaken for a possible tic disorder if the proper patient monitoring is not conducted during diagnosis.
According to a 2010 report based on a survey of caregivers of people with DLB, 78% of cases were initially misdiagnosed.
The drug was generally well-tolerated among study participants.
Patients experienced a 50% improvement in tremor and motor function.
Neurology Advisor Articles
- New Sleep Apnea Clinical Practice Guidelines
- International League Against Epilepsy Updates Epilepsy Classification System
- In Refractory Status Epilepticus, Lacosamide May Be a Good Option
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- The Handoff: Your Week in Neurology News - 3/23/17
- Q&A: Strategies for Transitioning Pediatric Patients to Adult Care
- Epilepsy Risk May Increase After Incident Depression
- Alzheimer's Caregiver Coping Program Does Not Increase Health Care Costs
- Valproate for Epilepsy Poses Greater Risk for Major Congenital Malformations
- VTE Recurrence Decreased With Rivaroxaban